Shots:

• The P-III SOURCE study involves assessing Tezepelumab (210mg- q4w) vs PBO in 150 adult patients as add-on therapy with patients maintained on their currently prescribed ICS + LABA- with/ out other asthma controller therapy for 48wks.
• The trial did not meet its 1EPs i.e.- reduction in the daily OCS dose- without loss of asthma control- the safety profile was consistent with previous trials. The therapy’s other efficacy parameters were similar to those observed in previous trials- including the P-III NAVIGATOR trial
• Tezepelumab is a human mAb targeting TSLP- being developed in collaboration with AstraZeneca and Amgen

 ­ Ref: AstraZeneca  | Image: Business Standard